Search

Accumulating evidence has suggested that long noncoding RNAs (lncRNAs) are involved in the progression of types of human cancers. It has been known that exosomes can mediate cell-cell crosstalk by transferring lncRNAs in tumor progression. This study aimed to investigate the role of exosomal lncRNA HEIH on cisplatin (DDP) resistance in tongue squamous cell carcinoma (TSCC). The expression of HEIH in human oral keratinocytes cell line (HOK), DDP-sensitive TSCC cell line (SCC4/S) and DDP-resistant TSCC cell line (SCC4/DDP) was measured. SCC4/S and SCC4/DDP cells were transfected with sh-HEIH to examine TSCC cell proliferation and apoptosis. The DDP-resistant exosomes were extracted and identified. The expression of miR‑3619-5p and TDGF in DDP-sensitive recipient cells was determined. The binding capacity between HEIH and miR‑3619-5p, along with miR‑3619-5p and TDGF was verified. HEIH expression was significantly upregulated in SCC4/DDP cells. Downregulation of HEIH inhibited DDP resistance and cell proliferation and promoted cell apoptosis. HEIH acted as a competing endogenous RNA (ceRNA) for miR‑3619-5p to upregulate HDGF expression. Exosomal HEIH promoted cell proliferation and drug resistance and inhibited cell apoptosis by sponging miR‑3169-5p and upregulating HDGF. Exosomal HEIH acted as a ceRNA for miR‑3619-5p to upregulate HDGF, thereby promoting DDP resistance in TSCC cells. [ABSTRACT FROM AUTHOR]

To investigate the relationship between dose parameters and tumor volume reduction ratio after 125I seed implantation for recurrent cervical squamous cell carcinoma, and to obtain the better parameters to predict the curative effect. 26 cervical squamous cell carcinoma patients with 30 lesions were studied retrospectively in our clinic. All patients underwent dose verification immediately after operation, and obtained postoperative D 90 (the minimum peripheral dose accepted by 90% target volume). The patients were followed up regularly. According to the CT images during the actual follow-up, the tumor volume reduction ratio at the end of t months (R t),the tumor volume reduction ratio 1 month after operation (R 1), the first month actual absorbed dose (D 1m), the first month efficacy corrected absorbed dose (D 1e), the first month sensitivity corrected absorbed dose (D 1s) and the t months actual absorbed dose (D t) were calculated. Curve fitting was performed for postoperative D90 and R1, and curve fitting was performed for postoperative D 90 , D 1m , D 1e , D 1s and R t to find the correlation between each parameter and tumor volume reduction ratio. The mean values of D 90 ,D 1m ,D 1e ,D 1s ,R t ,R 1 were (105.4±22.8) Gy,(30.9±7.4)Gy,(37.1±8.9)Gy,(37.8±11.6)Gy,(39.4±17)%,(20.4±12)%. Postoperative D 90 and R 1 , postoperative D 90 , D 1m , D 1e , D 1s andR t all have positive relationship. The equations are as follows y=6.856×10-7x3-2.66×10-4x2+0.031x-0.879(R2=0.139),y=1.573×10-6x3-4.47×10-4x2+0.045x-0.967(R2=0.027),y=7.11×10-5x3-0.07x2+0.193x-1.402(R2=0.043),y=3.546×10-5x3-0.003x2+0.108x-0.744(R2=0.126),y=1.022×10-5x3-0.001x2+0.048x-0.275(R2=0.243). PostoperativeD 90 , D 1m , D 1e and D 1s were positively correlated with postoperative tumor volume reduction ratio, which can be used to predict the efficacy of primary recurrent cervical squamous cell carcinoma patients with particle implantation. Compared with D 90 and D 1m , and D 1e , D 1s can be better predictors. [ABSTRACT FROM AUTHOR]